Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 BMS’ Belatacept BLA Accepted for Review | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

BMS’ Belatacept BLA Accepted for Review

Bristol-Myers Squibb’s BLA for belatacept has been accepted for filing and review by the FDA.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bristol-Myers Squibb’s BLA for belatacept has been accepted for filing and review by the FDA. The drug is currently in Phase III development for use in kidney transplantation.

“Belatacept has the potential to address significant unmet medical needs of transplant patients,” said Elliott Sigal, M.D., Ph.D., executive vice president, chief scientific officer and president, R&D, Bristol-Myers Squibb. “We are pleased the FDA has accepted our submission and we look forward to continuing to work with the agency.”

Sign up today for Contracting & Outsourcing 2009!
contractpharma.com/2009conference

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters